IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay

IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.

Source: MarketWatch

Technology

Congress passed the Social Security Fairness Act. Millions of people could see more in benefits as a result.

21. December 2024

Earnings

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

20. December 2024

Technology

This is what the happiest people 'get right' at an early age, says director of Harvard's 86-year happiness study

20. December 2024

Technology

Netflix secures U.S. rights to the FIFA Women's World Cup in 2027, 2031

20. December 2024

IGM Biosciences’ stock tumbles as analysts weigh in on pivot plan with dismay

Related Articles

Congress passed the Social Security Fairness Act. Millions of people could see more in benefits as a result.

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

This is what the happiest people 'get right' at an early age, says director of Harvard's 86-year happiness study

Netflix secures U.S. rights to the FIFA Women's World Cup in 2027, 2031